Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + GC neoadjuvant therapy for locally advanced bladder cancer
ChiCTR2100049108Phase 4Not yet recruiting
- Sponsor
- Baotou Cancer Hospital
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in bladder cancer, sponsored by Baotou Cancer Hospital. Primary endpoint: pathologic complete response rate. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on ChiCTR2100049108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049108.